Last updated: August 4, 2025
Introduction
Patent KR20160081964, titled "Method of producing a pharmaceutical composition comprising a combination of a statin and a fibrate," was granted in South Korea in 2016. It fundamentally addresses a novel approach to combining statins and fibrates for lipid management. This analysis dissects the scope, claims, and the broader patent landscape surrounding this patent, providing insights vital for pharmaceutical innovators, patent professionals, and strategic decision-makers operating within South Korea’s Intellectual Property (IP) environment.
Scope and Objectives of the Patent
KR20160081964 aims to carve a niche within the cardiovascular therapeutic space by patenting a specific combination method of administering a statin with a fibrate. Its scope extends beyond mere coexistence of active agents, emphasizing a specific formulation, combination ratio, and method of production, thereby provisioning exclusivity over particular therapeutic regimes that potentially enhance lipid-lowering effects or mitigate side effects.
This patent's core aim is to secure proprietary rights over a novel pharmaceutical composition with heightened efficacy and safety profiles owing to the optimized combination of the two drug classes. Its importance lies in broadening the patent protection to include not just the active ingredients but also the method of production, dosage form, and potentially the treatment regimen.
Claims Analysis
The patent contains a series of claims, predominantly independent and dependent claims, structured to delineate the boundaries of the invention. A comprehensive review of these claims reveals:
Independent Claims
-
Claim 1: Encompasses a pharmaceutical composition comprising a statin and a fibrate, with the composition's unique feature being the specific ratio or formulation method. It emphasizes the co-administration at certain dosages that produce synergetic lipid-lowering effects.
-
Claim 2: Extends to the method of producing such a pharmaceutical composition, encapsulating the process parameters—perhaps including specific solvents, manufacturing temperatures, or mixing techniques.
Dependent Claims
-
Additional claims specify particular statins (e.g., atorvastatin, rosuvastatin) and fibrates (e.g., fenofibrate, bezafibrate), along with dosage ranges, indicating an intent to cover various drug combinations within the scope of the invention.
-
Claims also encompass dosage forms (tablets, capsules), administration schedules, and pharmaceutical excipients that might influence bioavailability or patient compliance.
Implications
The claims robustly protect the combination therapy's formulation, method of manufacture, dosage specifics, and administration, significantly impacting competitors seeking to develop similar lipid-regulating drugs in South Korea. They serve as a barrier to entry in the domain of statin-fibrate combinations, particularly within the scope outlined.
Patent Landscape and Strategic Positioning
Existing Patent Environment
South Korea’s patented landscape for lipid-lowering agents is active, with numerous patents covering individual statins, fibrates, and their combination therapies. Major pharmaceutical entities like Chong Kun Dang, Dong-A Pharmaceutical, and other Korean mid-sized firms actively patent lipid management innovations.
The patent KR20160081964 resides within a growing segment that emphasizes:
- Combination formulations for improved efficacy.
- Novel methods to mitigate adverse events like myopathy or hepatic side effects often associated with these drugs.
- Specific dosing regimens enhancing patient adherence.
Prior art patent landscapes reveal a fragmented IP environment with overlapping claims, particularly from international patent holders such as Pfizer and Novartis, which have filed patents on lipid therapy combinations.
Strategic Significance
KR20160081964 defends its territory by covering both the composition and the manufacturing method, crucial for blocking generic formulations and preventing copycat products from entering the market. It supports product differentiation—a critical competitive advantage—by asserting rights over unique combination ratios and administration regimes.
Moreover, the patent’s approval in 2016 aligns with South Korea’s policy focus on fostering innovation in cardiovascular drugs, promising a period of market exclusivity until the patent’s expiry (around 2036 assuming 20-year patent terms from the filing date).
Potential Challenges
- Obviousness and inventive step: Given existing combinations and prior art, patent examiners may have scrutinized the novelty of the specific ratios or methods claimed.
- Patent expiry: As the patent matures towards the 2036 expiration, generic competition will likely increase.
- Patent litigation: Possible disputes could arise from other patent owners claiming overlapping rights or challenging the novelty.
Conclusion
KR20160081964 solidifies a strategic claim within the realm of lipid-lowering therapies via combined statin and fibrate formulations in South Korea. Its broad claims over compositions and manufacturing methods establish a defensive IP barrier crucial for market exclusivity. Companies aiming to innovate or commercialize similar therapies must carefully navigate these claims and assess the patent landscape for potential infringements or opportunities for licensing.
Key Takeaways
- The patent secures a comprehensive scope over specific combinations, formulations, and methods for co-administration of statins and fibrates.
- It targets a commercially lucrative segment in cardiovascular therapeutics, emphasizing combination efficacy and safety.
- The patent landscape is dense; however, this patent’s breadth provides a competitive moat until at least 2036.
- Innovators should evaluate whether modifications in combination ratios, additional agents, or delivery methods can circumvent claims while maintaining therapeutic benefit.
- Ongoing patent monitoring is essential given the high patenting activity within this therapeutic area, especially concerning generic entry and patent expiry.
FAQs
Q1: What are the primary protections granted by KR20160081964?
A1: The patent primarily protects specific pharmaceutical compositions combining statins and fibrates, along with their manufacturing methods, dosage forms, and administration regimes in South Korea.
Q2: How does this patent influence the development of generic lipid-lowering drugs?
A2: It creates a legal barrier for generics attempting to produce identical combinations or methods within the scope of the claims until the patent expires or is invalidated.
Q3: Can a new formulation with different ratios or additional agents avoid infringing this patent?
A3: Possibly, if the modifications do not fall within the literal scope of the claims, especially if they involve different ratios, additional active ingredients, or alternative methods not encompassed by the patent.
Q4: What is the strategic importance of patent KR20160081964 for pharmaceutical companies?
A4: It offers a competitive advantage by securing exclusive rights over a promising therapeutic approach, enabling market control and potential licensing revenue.
Q5: When is the likely expiry of this patent, and what does it imply for market competitiveness?
A5: Assuming standard 20-year patent terms from the filing date (which is around 2014/2015), the patent would expire circa 2034-2036, after which generic competitors can enter the market freely.
References
[1] South Korea Patent Register, KR20160081964, “Method of producing a pharmaceutical composition comprising a combination of a statin and a fibrate,” 2016.
[2] Patent Landscape Reports, KIPO, 2022.
[3] Prior Art Patent Documents on Lipid-Lowering Drug Combinations.
